Dare Bioscience More Than Double After Bayer Licensing Deal

Data : 13/01/2020 @ 17:04
Fonte : Dow Jones News
Titolo : Bayer AG (BAYN)
Quotazione : 70.5  -3.59 (-4.85%) @ 17:35
Quotazione Bayer Grafico

Dare Bioscience More Than Double After Bayer Licensing Deal

Grafico Azioni Dare Bioscience (NASDAQ:DARE)
Storico

2 Mesi : Da Dic 2019 a Feb 2020

Clicca qui per i Grafici di Dare Bioscience

By Chris Wack

 

Dare Bioscience Inc. (DARE) shares more than doubled to $1.85 in heavy trading after the company said it signed a licensing agreement with Bayer (BAYN.XE).

Volume at midmorning was 26 million shares, compared to the 65-day average volume of 252,000 shares.

Bayer may commercialize Dare's investigational contraceptive product Ovaprene in the U.S. once approved by the U.S. Food and Drug Administration, Dare said.

Dare said it is entitled to receive commercial milestone payments potentially totaling $310 million in addition to double digit tiered royalties on sales.

Dare said it plans to file an investigational device exemption for Ovaprene in the first half of 2020 and, pending the U.S. Food and Drug Administration's review and clearance of the IDE, to initiate a pivotal contraceptive effectiveness and safety clinical study of Ovaprene in the second half of 2020.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

January 13, 2020 10:49 ET (15:49 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
La tua Cronologia
BIT
BMPS
Monte Pasc..
BITI
FTSEMIB
FTSE Mib
BIT
UCG
Unicredit
NASDAQ
AAPL
Apple
FX
EURUSD
Euro vs Do..
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.

Registrati ora per creare la tua watchlist personalizzata in tempo reale streaming.

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

P: V:it D:20200224 21:57:00